Karan Thapar in conversation with Dr K. Srinath Reddy of the Public Health Foundation of India.
In an interview with Karan Thapar for The Wire, Dr K. Srinath Reddy, president of the Public Health Foundation of India, discusses the efficacy of a single dose of AstraZeneca’s Covishield against the Delta (B.1.167.2) variant and what is a safe interval between the two doses.
Dr Reddy discusses three studies, drawing out each time how they corroborate or reinforce concerns initially expressed by Public Health England about the inadequacy of a single dose of the AstraZeneca vaccine vis-à-vis the Delta variant. He said the three studies show that “the science is reasonably unequivocal and widely spaced doses of AstraZeneca’s Covishield is not the right way to go”.
He further said the May 13 policy which extended the gap between two doses up to 16 weeks must be reversed and the gap should be reduced to eight weeks.